EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Recruiting now · Phase 2

Conditions studied: Breast Cancer

In brief

This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

Key facts

Study ID

NCT06897488

Run by

M.D. Anderson Cancer Center

People needed

300

Starts

2025-07-17

Expected to finish

2030-12-31

Last updated by the study team

2026-05-15

Who can join

Age: 60 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of pathologically-confirmed invasive breast cancer
• Age ≥ 60 years
• Treatment with breast conserving surgery
• Pathologic T stage of T1 or T2 with total tumor size ≤ 3cm including any component of DCIS that may exist in conjunction with invasive disease
• Ki-67 . 20% and/or Oncotype 0-10 (Ultra Low)
• Final surgical margins negative, defined as no tumor on ink. Lobular carcinoma in situ involving the final surgical margin will be disregarded.
• Tumor must be estrogen receptor positive, progesterone receptor positive and HER2Neu non-amplified as per current College of American Pathologists guidelines
• Clinical nodal stage cN0
• If pathologic nodal staging is obtained, then pN0 or pN0(i+)
• Patients have had or have a scheduled discussion with a breast medical oncologist regarding adjuvant treatment options
• Patients who have met criteria 4.1.1-4.1.9 who never initiate endocrine therapy OR who initiate adjuvant endocrine therapy but discontinue it within 6 months of initiation * In some clinical scenarios, patients may have a particularly small volume of tumor, making it not be feasible for all of these biomarkers to be evaluated. In this scenario, if the PI and/or Protocol Collaborators are able to document that a patient is being treated as if they have luminal A (biologically favorable) breast cancer then the patient is eligible for enrollment if all other eligibility criteria are met.

You may not qualify if…

• Node positive disease (N1-3)
• Metastatic disease (M1)
• Grade 3 disease and lymphovascular space invasion in the tumor
• Synchronous bilateral breast cancer
• Receipt of neoadjuvant therapy
• Diagnosis of a collagen vascular disease associated with an increased incidence of radiation toxicities such as scleroderma or systemic lupus erythematosis
• Diagnosis of other cancer within the prior 5 years, excluding basal or squamous cell carcinoma of the skin that has been treated
• Patient with psychiatric illness/social situations that would limit compliance with study requirements
• Prior radiotherapy to the index breast or recurrent cancer of the breast
• Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2

Where it is running

• The University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.